Concerns are mounting over the German government’s response to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), with former Health Minister Karl Lauterbach publicly criticizing the current level of funding allocated to research. Lauterbach, now chair of the Bundestag’s research committee, has described the situation as a failure on the part of the state, highlighting the significant discrepancy between the need and the current investment.
Estimates suggest the number of individuals affected by ME/CFS in Germany has nearly doubled since the onset of the COVID-19 pandemic, now reaching approximately 650,000. This increase has amplified calls for greater attention and resources dedicated to understanding and treating the debilitating condition.
Lauterbach’s criticism centers on the comparatively modest sums currently earmarked for research. He expressed dismay at the ongoing debate within the governing coalition regarding whether to allocate €10 or €15 million, deeming both figures inadequate. He argued that a minimum investment of €1 billion would be necessary to properly address the scope of therapeutic research required.
ME/CFS is a complex neurological, immunological and metabolic illness characterized by a worsening of symptoms following physical, mental, or emotional exertion. Even seemingly minor stimuli, such as light, noise, or slight physical activity, can trigger severe exacerbations in severely affected individuals. Many experience prolonged bed rest, require caregiving, or face permanent disability. Currently, there are no medications that definitively cure the condition; therapeutic strategies primarily focus on managing symptoms and improving quality of life. Lauterbach emphasized that promises made to those affected have not been fully realized and a significant increase in research funding is urgently needed.